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Abstract
Background—Accumulating evidence suggests the origin of Juvenile Myelomonocytic 
Leukemia (JMML) is closely associated with fetal development. Nevertheless, the contribution of 
embryonic progenitors to JMML pathogenesis remains unexplored. We hypothesized that 
expression of JMML-initiating PTPN11 mutations in HSC-independent yolk sac erythromyeloid 
progenitors (YS EMPs) would result in a mouse model of pediatric myeloproliferative neoplasm 
(MPN).
Results—E9.5 YS EMPs from VavCre+;PTPN11D61Y embryos demonstrated growth 
hypersensitivity to GM-CSF and hyperactive RAS-ERK signaling. Mutant EMPs engrafted the 
spleens of neonatal recipients, but did not cause disease. To assess MPN development during 
unperturbed hematopoiesis we generated CSF1R-MCM+;PTPN11E76K;ROSAYFP mice in which 
oncogene expression was restricted to EMPs. YFP+ progeny of mutant EMPs persisted in tissues 
one year after birth and demonstrated hyperactive RAS-ERK signaling. Nevertheless, these mice 
had normal survival and did not demonstrate features of MPN.
Conclusions—YS EMPs expressing mutant PTPN11 demonstrate functional and molecular 
features of JMML but do not cause disease following transplantation nor following unperturbed 
development.
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Introduction
Juvenile Myelomonocytic Leukemia (JMML) is a pediatric myeloproliferative neoplasm 
(MPN) caused by mutations in RAS-ERK signaling genes. Gain of function PTPN11 
mutations are the most frequent cause of JMML, and are present in ∼35% of cases 
(Sakaguchi et al., 2013; Caye et al., 2015; Stieglitz et al., 2015). Patients suffer from 
monocytosis, anemia, thrombocytopenia, hepatosplenomegaly, and have a poor overall 
survival (Chan et al., 2009b; Locatelli and Niemeyer, 2015). Recent evidence has implicated 
a developmental origin to this disease. Children present very young with a median age of <2 
years. Patients frequently have elevated levels of fetal hemoglobin and their bone marrow 
cells have a gene expression signature characteristic of fetal progenitors (Weinberg et al., 
1990; Helsmoortel et al., 2016). Furthermore, retrospective analysis suggests that the 
majority of somatic JMML-initiating mutations occur before birth (Kratz et al., 2005; 
Matsuda et al., 2010; Stieglitz et al., 2015). Nevertheless, the identity of the JMML-initiating 
cell remains controversial.
The first murine hematopoietic stem cell (HSC) emerges around E11.0 in the aorta-gonad-
mesonephros region (Muller et al., 1994; Boisset et al., 2010). The HSC migrates to the fetal 
liver, expands, and seeds the bone marrow around birth (Christensen et al., 2004). The 
emergence of HSCs is preceded by sequential waves of hematopoiesis that originate in the 
extraembryonic yolk sac (YS) and consist primarily but not exclusively of progenitors with 
limited differentiation and self-renewal potential (Frame et al., 2013; Lin et al., 2014). The 
first HSC-independent wave consists of bipotent megakaryocytic-erythroid progenitors 
(MEP) and myeloid-restricted progenitors (Mac-CFC) (Moore and Metcalf, 1969; Bertrand 
et al., 2005; Tober et al., 2007). These arise directly from mesoderm around E7.0 and are 
termed primitive due to their morphology. A second HSC-independent wave begins around 
E8.25 with the emergence of erythromyeloid-progenitors (EMPs) via an endothelial-to-
hematopoietic transition (Palis et al., 1999; Lux et al., 2008; Frame et al., 2016). EMPs seed 
the fetal liver around E10.5 where they give rise to enucleated erythrocytes and diverse 
myeloid progeny including neutrophils, monocytes, and macrophages (Chen et al., 2011; 
McGrath et al., 2015). Following EMPs, lymphoid restricted progenitors and multilineage 
neonatal repopulating cells emerge in the YS prior to the first HSC (Yoder et al., 1997; 
Yoshimoto et al., 2010; Yoshimoto et al., 2012).
Recent evidence has highlighted the importance of EMPs in development. EMPs are integral 
for in utero vascular remodeling and sterile inflammatory signals from EMP-derived 
myeloid progeny promote the emergence of HSCs (DeFalco et al., 2014; Espin-Palazon et 
al., 2014; Li et al., 2014; Kasaai et al., 2017). Furthermore, loss of EMPs is not compatible 
with life since their progeny are required to sustain the embryo during the late fetal period 
when HSC-dependent progenitors are proliferating (Mucenski et al., 1991). Finally, whereas 
initial studies suggested EMPs had a transient role in development, recent work has proven 
that the progeny of EMPs persist into adulthood as tissue resident macrophages 
(Samokhvalov et al., 2007; Ginhoux et al., 2010; Schulz et al., 2012; Kierdorf et al., 2013; 
Epelman et al., 2014; Gomez Perdiguero et al., 2015; Hoeffel et al., 2015). YS-derived 
macrophages are present in the majority of organs at birth, and undergo gradual replacement 
by HSC-derived progeny. The rate of this replacement varies by tissue; it is very rapid in the 
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gut, whereas it is delayed in the spleen, liver, and heart. Importantly, there is negligible 
replacement of brain YS-derived macrophages. The majority of microglia retain an 
embryonic origin life-long, even after HSC transplant (HSCT) (Kennedy and Abkowitz, 
1997; Ginhoux et al., 2010; Hashimoto et al., 2013).
The contribution of YS progenitors to JMML is unknown. Several lines of evidence—in 
addition to the disease's in utero origin and fetal characteristics—suggest that EMPs may 
contribute to the pathogenesis of this disease. JMML has been successfully modelled with 
patient-derived induced pluripotent stem cells (iPSCs) (Gandre-Babbe et al., 2013; Mulero-
Navarro et al., 2015). However, iPSCs cannot give rise to HSCs and can only recapitulate 
YS-like HSC-independent hematopoiesis (Vanhee et al., 2015; Buchrieser et al., 2017). This 
suggests that YS-derived progeny will have defining features of JMML. Additionally, 
whereas HSCT is the only curative treatment for JMML, up to 52% of patients will relapse 
(Locatelli et al., 2005; Olk-Batz et al., 2011) suggesting that malignant JMML cells are 
uniquely resistant to myeloablation. Since tissue resident macrophages in both mice and 
humans are also relatively resistant to myeloablation, we hypothesized that EMPs may 
contribute to JMML relapse via their long-lived myeloid progeny (Kennedy and Abkowitz, 
1997; Haniffa et al., 2009; Hashimoto et al., 2013).
Previous studies have struggled to identify the contribution of YS progenitors to disease. 
One study used transplantation experiments to evaluate the HSC-dependent vs. HSC-
independent origin of tumor-associated macrophages (Gordon et al., 2017). However, 
transplantation is not a reliable approach since YS-derived macrophages outside the brain 
are gradually replaced by donor contributions – albeit at a slower rate than HSC-derived 
myeloid populations. Other studies have assessed the aberrant function of mutation-
expressing YS progenitors ex vivo and have shown them to have unique disease phenotypes. 
For instance, YS-derived megakaryocytes are uniquely hyperproliferative following 
expression of truncated GATA1 (Li et al., 2005). However, this study was not able to assess 
the postnatal consequences of mutations restricted to YS progenitors.
In our study, we use complementary approaches to evaluate the consequences of JMML-
associated gain-of-function PTPN11 mutations in EMPs. In addition to ex vivo assays and 
transplantation experiments, we take advantage of inducible lineage tracing Cre-loxP 
techniques to study the postnatal effects of mutant EMPs. We thereby definitively address 
our hypothesis that restricted expression of mutant PTPN11 in YS EMPs will be sufficient 
for the emergence of MPN in a mouse model of JMML. We demonstrate that YS EMPs 
expressing gain-of-function PTPN11 have defining features of JMML, including growth 
hypersensitivity to GM-CSF and RAS-ERK hyperactivation. Nevertheless, mutant YS EMPs 
were not able to give rise to MPN following transplantation nor following unperturbed 
development despite the durable persistence of their progeny in adult mice.
Results
We hypothesized that in utero expression of the PTPN11D61Y JMML-initiating mutation 
would result in the rapid onset of MPN in mice. To test this hypothesis we activated the 
oncogene in early hematopoietic progenitors using VavCre, whose expression begins in fetal 
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blood cells (Ghiaur et al., 2008). VavCre+; PTPN11D61Y mice were viable and born at 
expected Mendelian ratio (Fig-1A), developed leukocytosis and monocytosis by 8 weeks of 
age, and had a median survival of 31 weeks (Fig-1B). Given that Mx1Cre+;PTPN11D61Y 
mice have a reported median survival of 45 weeks, our results suggest that oncogene 
expression by in utero progenitors exacerbates progression of PTPN11D61Y-induced MPN 
(Chan et al., 2009a).
To confirm that embryonic progenitors expressing PTPN11D61Y manifested features of 
MPN, we assayed their growth in methylcellulose medium with increasing doses of GM-
CSF. Both E14.5 fetal liver (FL) progenitors and E9.5 YS progenitors from VavCre
+;PTPN11D61Y mutant embryos had markedly greater colony formation at low doses of 
GM-CSF compared to littermate controls (Fig-1C,D). To evaluate if this GM-CSF 
hypersensitivity was due to hyperactive RAS signaling, we measured the phosphorylation 
(p-) of ERK. Mutant cells cultured from E14.5 FL had markedly elevated p-ERK levels both 
at baseline and following 30min stimulation with 10ng/ml GM-CSF, as measured by western 
blot (Fig-1E). Additionally, mutant cells cultured from E9.5 YS also had elevated p-ERK 
and p-STAT5 levels as measured by intracellular flow cytometry (Fig-1F). These results 
demonstrate that both HSC-dependent FL progenitors and HSC-independent YS cells have 
defining functional features of JMML. To determine the identity of the hyperactive YS 
progenitor, we sorted Ter119- CD41dim cKit+ YS EMPs from E9.5 VavCre+;PTPN11D61Y 
mutants and littermate controls. Mutant EMPs produced greater numbers of colonies at the 
tested concentrations of GM-CSF (Fig-1G), providing evidence that the EMP is the YS 
progenitor responsible for the observed features of JMML.
Tissue macrophages are the durable progeny of EMPs and they are relatively resistant to 
myeloablation compared to other myeloid cells. As such, mutant EMPs may contribute to 
JMML relapse following HSCT via their myeloablation-resistant progeny. To test this 
notion, we devised a therapeutic HSCT in which VavCre+;PTPN11D61Y mice were treated 
with adoptive transfer of healthy CD45.1+ BM cells (Fig-2A). We hypothesized that 
recipients would relapse following poor donor engraftment. We transplanted 12-24week old 
lethally irradiated mutant and littermate animals (CD45.2+) with 5×105 heathy congenic 
CD45.1+ BM cells. We were surprised to observe that donor cells engrafted more readily in 
mutant recipients than in control recipients (Fig-2B). Furthermore, the engrafted cells 
preferentially gave rise to CD11b+ myeloid cells and to fewer CD3+ T-lymphocytes 
(Fig-2C). Despite this robust engraftment, mutant recipient mice rapidly succumbed after 
transplantation, with a mean survival of 16 weeks (Fig-2D). To evaluate whether limiting 
donor cell numbers affected post-transplant survival, we repeated the experiment using 
1×107 CD45.1+ donor BM cells. Mutant mice nevertheless succumbed with a median 
survival of 18 weeks (Fig-2D).
At analysis, moribund mutant recipients had a hypercellular BM with an effacement of the 
normal splenic follicular architecture (Fig-2F,G). We were surprised, however, to find 
markedly enlarged thymuses in moribund mutants (not shown). Subsequent analysis 
confirmed that both the BM and spleen were filled with CD45.2+ recipient-derived CD4+ 
CD8+ cells, which are indicative of T-cell leukemia/lymphoma (T-ALL) (Fig-2E). 
Transplantations of BM and spleen cells from HSCT-treated mutants into CD45.1 recipients 
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confirmed that the CD45.2+ T-ALL disease could be propagated and was neoplastic (not 
shown). From these experiments we concluded that healthy donor cells could efficiently 
engraft mutant recipients and preferentially gave rise to myeloid progeny. Despite this robust 
engraftment, mutants died after transplantation due to the emergence of a recipient-derived 
T-ALL, which could be propagated upon transplantation. Importantly, this finding contrasts 
with JMML patients who rarely demonstrate emergence of T-ALL and primarily relapse 
with MPN following HSCT (Cooper et al., 2000).
PTPN11D61Y murine models have indolent disease progression. We reasoned that a different 
JMML-associated PTPN11 mutation that causes more rapid disease onset would help 
accentuate our findings. We chose the conditional PTPN11E76K mouse because it succumbs 
to MPN more rapidly than PTPN11D61Y mice and because this mutation has been 
documented to occur in utero in JMML patients (Matsuda et al., 2010; Xu et al., 2011).
Sorted YS EMPs from E10.0 VavCre+;PTPN11E76K were growth hypersensitive to GM-
CSF, further demonstrating that mutated HSC-independent progenitors have features of 
JMML (Fig-3A). Surprisingly, when we mated VavCre mice with PTPN11E76K/+ mice we 
did not obtain viable VavCre+;PTPN11E76K progeny (Fig-3C). Analyses of E10.5 embryos 
showed mutants were smaller, less developed, and had a pale YS and AGM region (Fig-3D). 
Subsequent analysis of E17.5 embryos confirmed that VavCre+;PTPN11E76K embryos were 
dying in utero (Fig-3D). This was in contrast to recent publications that reported this model 
to be viable and develop MPN (Dong et al., 2016; Liu et al., 2016). This discrepancy is 
likely due to the use of different VavCre strains. Prior studies used the VavCreStadtfeld strain, 
which has minimal expression in endothelial and stromal cells. In contrast, the VavCreCroker 
and VavCredeBoer strains in our studies have pronounced expression in endothelial cells 
which may cause the prenatal lethality we observed (de Boer et al., 2003; Croker et al., 
2004; Stadtfeld et al., 2007).
Despite the in utero lethality of VavCreCroker;PTPN11E76K mice, their E10.0 YS 
hematopoietic progenitors gave rise to a normal distribution of BFU-E, CFU-GM, and CFU-
GEMM colonies (Fig-3B). We therefore tested whether YS progenitors could give rise to 
MPN upon transplantation. We transplanted 1 embryo equivalent (e.e.) FACS-sorted YS 
EMPs from E10.5 VavCre+;PTPN11E76K embryos i.v. into 150cGy sublethally irradiated 
neonatal NSG CD45.1+ recipients. We also transplanted CD45- Ter119- cKit+ VE-Cadherin
+ hemogenic endothelial populations from the AGM of the same embryos (Rybtsov et al., 
2011). Prior work has demonstrated neonatal recipients are uniquely capable of supporting 
YS progenitor engraftment (Yoder and Hiatt, 1997; Yoder et al., 1997; Yoshimoto et al., 
2010; Yoshimoto et al., 2012; Arora et al., 2014). Nonetheless, we did not observe 
peripheral blood engraftment or elevated leukocyte counts in recipients of either YS or AGM 
cells (Fig-3E). This finding is consistent with recent studies that showed purified YS EMPs 
did not contribute to circulating leukocytes following transplantation (McGrath et al., 2015).
At tissue analysis 18 weeks post-transplant, we were surprised to discover that donor EMPs 
had engrafted in recipient spleens as F4/80+ CD11bdim macrophages (Fig-3F). The 
engraftment of splenic macrophages was more robust in recipients of YS EMPs than of 
AGM VECad+ cells. Notably, whereas the most prominent progeny of EMPs are microglia, 
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we did not detect any CD45.2+ cells in the brains of EMP recipients (Fig-3G). These results 
are consistent with previous studies that showed differences in progenitor differentiation 
under native and transplant settings (Boyer et al., 2011; Busch et al., 2015). Our findings 
highlight the pitfalls of models that rely on transplantation, which identify progenitor 
potentials under non-native conditions (Schlenner and Rodewald, 2010; Busch and 
Rodewald, 2016). We concluded that it would not be feasible to definitively evaluate the 
contribution of HSC-independent progenitors to JMML using the VavCre model.
We therefore turned to the CSF1R Mer-Cre-MER (MCM) model which can restrict Cre 
activity to YS EMPs following 4-hydroxytamoxifen (4OHT) injection of pregnant dams at 
E8.5 (Qian et al., 2011; Gomez Perdiguero et al., 2015). We mated CSF1R-MCM
+;ROSAYFP/YFP studs with PTPN11E76K/+ dams to generate mutant CSF1R-
MCM;ROSAYFP/+;PTPN11E76K/+ progeny (CSF1R-MCM;PTPN11E76K) (Fig-4A). In these 
animals, Cre-mediated recombination results in the expression of both PTPN11E76K and 
yellow fluorescent protein (YFP). As such, cells expressing the oncogene can be monitored 
using flow cytometry. 24 hours after oncogene activation by 4OHT injection, mutant and 
littermate embryos had equal frequencies of YS EMPs (Fig-4B). Additionally, the frequency 
of YFP+ EMPs was equivalent in both mutants and controls. (Fig-4C). This indicated that 
mutants and littermates had equivalent activity of the Cre recombinase. We proceeded to 
assess proliferation of EMPs using Ki67 staining. EMPs from mutant YS did not have 
increased Ki67 expression compared to their littermates (Fig-4D). Additionally, p-ERK 
levels in both YFP+ and YFP- EMPs from mutant embryos was not increased following 
GM-CSF stimulation compared to control EMPs (Fig-4E). The lack of cell cycle and 
signaling differences may be attributed to the highly proliferative nature of embryonic 
hematopoietic progenitors as compared with their adult counterparts (Bowie et al., 2007). 
We reasoned that any oncogenic effects of PTPN11E76K mutation would only be evident 
postnatally, once hematopoietic progenitors enter a state of relative quiescence.
We proceeded to generate a cohort of CSF1R-MCM; PTPN11E76K animals that had been 
exposed to 4OHT at E8.5 (Figure-5A). Mutants were weaned at a normal Mendelian 
frequency of 24% and were physically indistinguishable from littermates (Fig-5B). We 
monitored all animals in this cohort with monthly peripheral blood draws (Fig-5C-G). As 
expected, we did not observe YFP+ cells in the peripheral blood, indicating that Cre was not 
active in HSCs. Over a 52 week period, we did not observe leukocytosis, anemia, or 
thrombocytopenia in mutant animals. Furthermore, we did not see evidence of 
myeloproliferation or skewing of leukocyte lineages. Over the course of the study, one 
mutant animal succumbed from an unclear cause and one littermate control succumbed to 
sporadic T-ALL (Fig-5H).
We considered that indolent MPN progression in these animals may not manifest in the 
peripheral blood and would only be evident upon tissue examination. We hypothesized that 
mutant adults would have a greater frequency of YFP+ macrophages compared to controls 
due to growth promoting effects of PTPN11E76K. However, upon analysis, mutant animals 
did not have hepatosplenomegaly and no YFP+ cells were detected in the BM and spleen 
(Fig-6A,B). Additionally, mutant animals had a normal distribution of leukocyte lineages in 
the BM and spleen, indicating absence of myeloid-biased differentiation. (Fig-6C,D).
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We proceeded to characterize macrophage populations in the brain, heart, and liver; the 
tissues with the greatest contribution from YS EMPs. Consistent with previous reports we 
saw high proportions of YFP+ microglia and measureable proportions of YFP+ heart and 
liver macrophages (F4/80bright CD11b+) (Fig-6E,F). Nonetheless, we did not observe 
differences in the frequency of YFP+ macrophages between CSF1R-MCM; PTPN11E76K 
and controls in any tissue. To determine whether the former presence of mutant splenic 
macrophages had evoked GM-CSF hypersensitivity in progenitors we performed colony 
forming assays. No difference in colony formation was observed between mutant and 
littermate samples (Fig-6G). To ensure that the PTPN11E76K allele was appropriately 
recombined, we confirmed the excision of the loxP-STOP-loxP cassette in brains of mutant 
animals (Fig-6H). We then assayed RAS-ERK signaling in freshly-isolated mutant and 
control microglia and confirmed that mutant cells had greater p-ERK levels (Fig-6J). These 
results suggest that in utero PTPN11E76K expression by YS EMPs gives rise to tissue 
macrophage populations with hyperactive RAS-ERK signaling that persist more than a year 
after birth. Nevertheless, these mutant EMPs did not cause overt signs of MPN such as 
monocytosis, anemia, and hepatosplenomegaly.
Discussion
We present the first study to directly assess the contribution of HSC-independent 
hematopoietic progenitors to pediatric neoplasms. We show that YS EMPs expressing 
mutant PTPN11 are hypersensitive to GM-CSF and have hyperactive RAS-ERK signaling. 
Nevertheless, EMPs expressing gain-of-function PTPN11 do not cause disease upon 
transplantation nor following in utero expression using the tamoxifen-inducible CSF1R-
MCM system.
Recent studies have provided tantalizing evidence for the potential contribution of 
embryonic HSC-independent hematopoiesis to JMML. The strikingly high relapse rate 
following HSCT suggests that myeloablation-resistant and HSC-independent populations 
contribute to disease emergence (Locatelli et al., 2013). YS EMPs admirably match these 
criteria: they give rise to tissue macrophage populations in diverse tissues that are long-lived 
and relatively resistant to myeloablation (Haniffa et al., 2009; Hashimoto et al., 2013; 
Epelman et al., 2014; Gomez Perdiguero et al., 2015). Second, JMML patients frequently 
acquire their disease-initiating mutations in utero (Matsuda et al., 2010; Stieglitz et al., 
2015). Finally, several studies have successfully modelled JMML using patient-derived 
iPSCs, whose differentiation mimics that of HSC-independent YS hematopoiesis (Gandre-
Babbe et al., 2013; Mulero-Navarro et al., 2015; Vanhee et al., 2015; Buchrieser et al., 
2017). This reasoning prompted us to hypothesize that expression of JMML-initiating 
mutations in embryonic HSC-independent progenitors would be sufficient for disease 
development (Chan and Yoder, 2013).
Our initial experiments with VavCre+;PTPN11D61Y mice demonstrated the feasibility of this 
hypothesis. These animals rapidly succumbed to MPN and their HSC-independent YS 
EMPs had two disease-defining features of JMML: growth hypersensitivity to GM-CSF and 
hyperactive RAS-ERK signaling. This suggested that YS progenitors may contribute to 
MPN emergence. However, transplantation of VavCre+;PTPN11E76K EMPs did not cause 
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disease in neonatal NSG recipients despite robust engraftment as splenic macrophages. The 
inability of mutant macrophages to cause disease further demonstrates that the aberrant 
peripheral monocytes in MPN are distinct from tissue macrophages. This finding is 
consistent with a growing literature that highlights functional, morphologic, and 
transcriptional differences between circulating and resident myeloid cells (Lavin et al., 
2014). Importantly, ours is the first study to demonstrate durable engraftment of EMPs 
following transplantation. Previous studies showed that transplantation of EMPs into adult 
recipients resulted in transient erythroid contributions but not leukocyte engraftment 
(McGrath et al., 2015). It is unclear, however, whether our engraftment was the result of 
oncogene-expressing EMPs or whether it was enabled by the use of neonatal recipients. 
Future studies will need to evaluate whether mutant PTPN11 or recipient age is the major 
determining factor permitting EMP engraftment.
Our study further highlights the challenges of transplantation experiments in studying 
disease initiating cells. The dominant progeny of EMPs in unperturbed hematopoiesis are 
microglia. Nevertheless, we observed EMP engraftment in the spleen but not the CNS 
following neonatal transplantation. Differences between in vivo differentiation and 
transplantation-evoked potentials among adult hematopoietic progenitors have also been 
shown (Schlenner and Rodewald, 2010; Busch and Rodewald, 2016). Additionally, we saw 
that VavCre+;PTPN11D61Y mice engrafted with healthy donor cells had disease 
exacerbation and rapidly succumbed to recipient-derived T-ALL. In contrast, non-irradiated 
animals expressing PTPN11D61Y die from MPN (Chan et al., 2009a). Our findings are 
consistent with other studies that showed frequent T-ALL emergence in irradiated mutant 
PTPN11-expressing animals due to impaired DNA repair (Liu et al., 2016). As such, our 
results emphasize that the same mutation may give rise to divergent disease manifestations 
in irradiated and non-irradiated animals.
Previous studies have implicated an abnormal hematopoietic microenvironment in the 
pathogenesis of JMML (Xu et al., 2013; Dong et al., 2016). This group demonstrated that 
non-mutated progenitors that occupy a mutant PTPN11-expressing niche have features of 
MPN including hyperactive RAS-ERK signaling and myeloid-biased differentiation. Our 
finding that healthy donor progenitors preferentially contribute to CD11b+ myeloid cells 
following transplantation into VavCre+;PTPN11D61Y animals is consistent with these earlier 
findings. Additionally, we show that disease reemergence in mutant animals following 
healthy donor HSCT is not caused by impaired engraftment. Rather, the greater frequency of 
CD45.1+ leukocytes in VavCre+;PTPN11D61Y recipients compared to controls suggests that 
that the mutant niche may evoke increased cycling among donor progenitors, potentially 
leading to premature exhaustion.
Our ex vivo analyses and transplantation experiments demonstrate the challenges of 
measuring the contribution of HSC-independent progenitors to disease. Previous studies also 
relied on transplantation experiments and/or isolation of in utero progenitors (Li et al., 2005; 
Gordon et al., 2017). However, these approaches prevent the analysis of postnatal effects of 
prenatal mutations. Our major advance was to adapt the lineage-tracing CSF1R-MCM 
system to restrict the expression of PTPN11E76K to EMPs and permit the normal birth and 
development of these mice. The concomitant use of the ROSAYFP reporter enabled us to 
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analyze the frequency and functional characteristics of mutant EMP progeny. We were thus 
able to show that mutant EMPs in CSF1R-MCM+;PTPN11E76K embryos did not have 
enhanced proliferation or hyperactive RAS-ERK signaling compared to littermates. After 
birth, no YFP+ EMP progeny were observed in the peripheral blood and no evidence of 
MPN was detected during year-long monitoring despite the persistence of YFP+ mutant 
macrophages in the brain, liver, and heart. Microglia in mutants had recombined their 
PTPN11E76K locus and had hyperactive RAS-ERK signaling. Nevertheless, these animals 
did not have diminished survival and they did not show signs of morbidity.
There are several possible explanations for the lack of disease in our cohorts. First, YS 
EMPs may not possess the differentiation potential required for fulminant MPN emergence. 
Indeed, whereas EMPs do give rise to neutrophils and monocytes, their long lived progeny 
are tissue resident macrophages, which are functionally, transcriptionally, and epigenetically 
distinct from the circulating myeloid populations that are expanded in JMML patients 
(Gosselin et al., 2014; Lavin et al., 2014). Additionally, healthy EMPs may already be so 
proliferative that PTPN11E76K had no effect on their cell cycle, as measured by Ki67. 
Furthermore, only 35% of E9.5 EMPs were targeted in our model. This is a much lower 
frequency than the >90% efficiency obtained from most conditional mouse models, such as 
Mx1Cre or VavCre. Finally, the CSF1R-MCM can only label EMPs between E8.5 and E9.5 
(Gomez Perdiguero et al., 2015; Hoeffel et al., 2015). In contrast, the transcriptional 
program that drives the emergence of EMPs begins between E6.5-E7.5, the first EMPs 
emerge at E8.25, continue to arise until at least E10.5, and proliferate until birth (Chen et al., 
2011; Tanaka et al., 2012; Tober et al., 2013). As such, our system labels only a minority of 
one subset of EMPs and it is possible that other HSC-independent progenitors, including 
distinct EMP subpopulations and neonatal repopulating cells, may respond differently when 
expressing PTPN11 mutations (Yoder et al., 1997; Sheng et al., 2015; Frame et al., 2016).
In conclusion, we present the first study to evaluate the contribution of HSC-independent 
hematopoietic progenitors to JMML. We show that YS EMPs expressing gain-of-function 
PTPN11 are hypersensitive to GM-CSF and have hyperactive RAS-ERK signaling. 
Nevertheless, mutant EMPs were not able to give rise to disease upon transplantation nor in 
the context of unperturbed development. Our findings suggest YS EMPs may be resistant to 
transformation by this mutation. We conclude that PTPN11E76K expression in a subset of 
YS EMPs does not result in an expansion of mutant macrophages and is not sufficient for 
MPN emergence in a mouse model of JMML.
Experimental Procedures
Mice
C57BL/6J, B6.SJL-Ptprca Pepcb/ (BoyJ), and NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) 
mice were bred in-house. LSL-PTPN11D61Y/+ mice were obtained from Dr. Gordon Chan 
and Dr. Benjamin Neel (U. Toronto, Canada). LSL-PTPN11E76K/+ mice were obtained from 
Dr. Cheng-Kui Qu (U. Emory, Atlanta, GA). ROSAYFP/YFP mice were obtained from Dr. 
Anthony Firulli (IUSM, Indianapolis, IN). CSF1R-Mer-Cre-Mer mice (#019098) were 
purchased from Jackson Labs and were back-crossed onto the C57B6 background for 6 
generations. VavCreCroker mice were mated with PTPN11E76K and were a gift from Dr. 
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David Williams (Boston Children's Hospital, Boston, MA). VavCredeBoer mice were mated 
with PTPN11D61Y and were a gift from Dr. Reuben Kapur (IUSM, Indianapolis, IN). Mice 
were identified by ear notches or toe clips. Genotyping was performed with conventional 
PCR using primers listed in the Appendix. Experimental and control animals were housed 
together in the same cages. All animal studies were performed with prior approval from the 
IUSM Institutional Animal Care and Use Committee.
Mouse hematologic analysis
Blood collections were done via tail vein into EDTA-coated tubes (Fisher #NC9628695). 
Counts were obtained using a HemaVet 950 (Drew Scientific). Blood smears and cytospins 
were stained using Modified Wright-Giemsa dyes on a Hematek 3000 system (Siemens). 
For subsequent flow cytometric analysis, up to 60ul of blood was aliquoted into 1ml of 
Blood Collection Medium (IMDM +10%FBS +1% Pen/Strep + 20U/ml Heparin (Sigma 
#H3149)).
Timed Matings
Male studs (10-26 weeks of age) were housed in separate cages and mated after at least 2-3 
days of acclimatization to their cage. In the evening one or two female mice (8-26 weeks of 
age) were moved to the stud cage. The following morning, successful matings were 
confirmed by visual inspection of a vaginal plug and assigned a gestational age of E0.5.
Tamoxifen Treatment
To induce recombinase activity in utero, pregnant dams were injected i.p. with 75ug/g 4-
hydroxy tamoxifen (Sigma #H6278) along with 37.5ug/g progesterone (Sigma #P0130). 
Litters of tamoxifen-treated dams were routinely delivered by C-section on E19.5 and raised 
by foster females.
Embryo Harvests
Pregnant females were euthanized by cervical dislocation followed by bilateral 
pneumothorax. The abdominal cavity was opened using sterile scissors and forceps. The 
uterine horns were removed and placed in a petri dish with sterile PBS. The uterine fascia, 
musculature, and placental tissues were sequentially removed using forceps to expose the 
YS-enclosed embryo. Embryo age was confirmed by counting somite pairs: E9.5 (20-26sp), 
E10.0 (27-32sp), E10.5 (33-37sp). Desired tissues were dissected out and placed into 
collection tubes containing PBS. Tissue digests were performed for 5-30min at 37°C in 
0.125% collagenase type I (Stem Cell Technologies #07902).
Ex Vivo Culture
Cells were cultured in a humidified incubator at 37°C, 5% CO2 in IMDM (Fisher 
#12440079), 10% FBS (Fisher #SH30070.03), 100 U/ml Penicillin/Streptomycin (Fisher 
#15140122), 440nM β-Mercaptoethanol (Sigma #M6250), and 2mM L-Glutamine (Fisher # 
25030-081). Yolk sac or fetal liver cells were differentiated into macrophages by culturing 
for 7 days in 10ng/ml M-CSF (Peprotech #315-02).
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Hematopoietic Cell Isolations
All tissues were kept on ice in PBS +2mM EDTA. Bone marrow cells were flushed from 
hindlimb bones. Spleens were triturated with glass cover slides. Livers, hearts, and brains 
were minced with razors and digested at 37°C in 0.2% collagenase D (Sigma 
#11088866001), 0.5% Dispase (Fisher #17105-041) and 50U/ml DNase I (Sigma 
#10104159001) for 60min. Enucleated RBCs were depleted as necessary using density 
gradient centrifugation in Histopaque (Sigma #10771) or RBC lysis buffer (Quiagen 
#158904). As needed, liver and brain suspensions were depleted of parenchymal cells and 
lipids via centrifugation through a 37% and 50% Percoll (Sigma #P1644) gradient, 
respectively.
Flow Cytometry
Cells were stained at a concentration of 1-5 × 107/ml in PBS +2% FBS + 2mM EDTA. 
Antibody concentrations were determined experimentally. If required, cells were fixed in 1% 
PFA (Fisher #50-980-487). For cell cycle analysis, stained cells were permeabilized with 
eBioscience Intracellular Fixation & Permeabilization Buffer Set (#88-8824-00). For 
Intracellular phospho-flow, cells were stimulated in an Eppendorf tube with GM-CSF 
(Peprotech #315-03), fixed in 1% PFA for 15min, and permeabilized using BD Perm Buffer 
III (#558050). Stained cells were analyzed using the BD LSR Fortessa, BD FACS CANTO 
II, or BD Accuri C6. Post run analysis was performed using FlowJo (Treestar).
Tissue Histopathology
Tissue samples were fixed in 4% PFA, dehydrated with ethanol, cleared with xylenes and 
embedded in paraffin. 5um sections were cut on a rotary microtome and stained with 
hematoxylin and eosin.
DNA isolation
Murine tails were digested for 1hr at 95°C in 50mM NaOH + 0.2mM EDTA, vortexed, 
pelleted, and then diluted to 100mM Tris buffer. Alternatively, DNA was isolated from 
tissues using the DNeasy Blood & Tissue Kit (Quiagen # 69504).
Hematopoietic Progenitor Colony Forming Assay
2×104 FL mononuclear cells, 2.5 ×105 spleen cells or 1/5 of total YS cells were plated in 
1ml of 30% methylcellulose in IMDM (Stemcell Technologies #M3120) supplemented with 
30% FBS, 2.2% Pen/Strep, 2.45mM L-Glutamine, and 440nM β-Mercaptoethanol (Sigma 
#M6250) and defined concentration of murine GM-CSF.
Transplantations
Adult recipients (8-24wks) were lethally irradiated with 700cGy+400cGy. Within 16hrs, 
donor cells were adoptively transferred via tail vein in 250ul PBS using a 28G insulin 
syringe (Fisher #BD 329461). A heat lamp and alcohol swab was used to engorge the vein. 
Neonatal NSG recipients (2 day-old) were sublethally irradiated with 150cGy. Immediately 
after irradiation, donor cells were adoptively transferred via facial vein in 30ul PBS using a 
30G needle and a 0.1ml syringe (Hamilton #1710).
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Western blots
Protein extracts were obtained by lysing cultured or primary cells for 30min on ice in 50mM 
HEPES, 150mM NaCl, 10% Glycerol, 1% Triton X100, 1.5mM MgCl2, 1mM EGTA, 
100mM NaF, 10mM NaPP, along with a protease inhibitor cocktail containing sodium 
vanadate, ZnCl2, PMSF (Sigma # 93482), and enzymatic inhibitors (Sigma # 
10837091001). Protein lysates were run using SDS-PAGE, transferred to nitrocellulose 
membranes. Blots were exposed using SuperSignal West Pico Chemiluminescent Substrate 
(Fisher #34080).
Statistical analyses
P-values were calculated using Graph Pad Prism 7.0. Two-tailed t-tests were used to 
compare two-variable experiments. Chi-squared analyses were used to compare birth ratios. 
Survival analyses were performed by Mantel-Cox log-rank tests. Two-way ANOVA analyses 
were used to compare changes in variables over time. All error bars represent SEM. P values 
<0.05 were considered significant. Notation: * p-value<0.05; ** p-value<0.01; *** p-
value<0.001; ns not significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. VavCre+;PTPN11D61Y E9.5 yolk sac EMPs have defining features of JMML
A) Genotype ratios at weaning of VavCre+ × PTPN11D61Y/+ matings; Chi-Squared p-
value=0.04. B) Overall survival of VavCre+ × PTPN11D61Y/+ progeny (N=12 mutants, 53 
littermates). C,D) 7 day methylcellulose colony formation of E14.5 FL cells (N=7 mutants, 7 
controls) and E9.5 YS cells (N=11 mutants, 7 controls). E) Ex vivo FL-derived macrophages 
were stimulated for 30min with 10ng/ml GM-CSF and lysates were probed with indicated 
antibodies. F) p-ERK and p-STAT5 signaling in ex vivo cultures of E9.5 YS-derived 
macrophages following 30min of 5ng/ml GM-CSF stimulation (N=5 biological replicates/
group from 2 independent experiments). G) Methylcellulose assay with E9.5 YS sorted 
Ter119- cKit+ CD41dim EMPs (N=2 pooled litters).
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Figure 2. VavCre+;PTPN11D61Y acquire T-ALL following healthy donor HSCT
A) Schematic of transplant. B) Donor engraftment in blood. C) Donor contribution to 
myeloid and lymphoid peripheral blood leukocytes. D) Overall survival of transplant 
recipients. E) Representative flow cytometry of CD45.2+ host-derived abnormal T-
lymphocytes in the BM and spleen of mutant recipients. Immunohistochemistry of F) BM 
and G) spleen of mutant and littermate transplant recipients.
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Figure 3. VavCre+;PTPN11E76K YS EMPs engraft neonatal recipients but do not give rise to 
MPN
A) 7 day colony formation from sorted Ter119- cKit+ CD41dim E10.0 YS EMPs (n=4 
embryos/group from 2 litters). B) Methylcellulose colony formation by mutant and 
littermate YS progenitors (N=3 litters, analysis by Chi-Squared test). C) Genotype ratio of 
animals weaned from VavCre+ × PTPN11E76K/+ matings (N=45 births). D) Representative 
images of E10.0 and E17.5 mutant and littermate embryos. E-G) YS and AGM progenitors 
from E10.5 VavCre+;PTPN11E76K embryos were transplanted into 2 day-old NSG neonatal 
recipients. E) Leukocyte counts of recipients (N=2 recipients/group). F) Representative 
gating of YS EMP-derived splenic macrophages in neonatal recipients. G) YS EMPs from 
mutant embryos do not contribute to microglial populations in engrafted animals.
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Figure 4. Analysis of CSF1R-MCM+;ROSAYFP;PTPN11E76K E9.5 EMPs
A) Schematic of mating strategy and 4-hyroxy tamoxifen (4OHT) administration to pregnant 
dams. B) Frequency of EMPs in E9.5 YS. C) Proportion of EMPs that are YFP+ following 
E8.5 4OHT. D) Ki67 expression in E9.5 YS EMPs (normalized to average median 
fluorescence intensity among EMPs in each litter). E) p-ERK expression among ex vivo 
E9.5 YS EMP-derived macrophages after stimulation with 20ng/ml (N=3 embryos/group).
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Figure 5. Peripheral blood analysis of CSF1R-MCM+;ROSAYFP;PTPN11E76K
A) Schematic of mating. All litters were born to dams who were injected with 4OHT at 
E8.5. B) Genotype ratios at weaning (N=14 mutants and 43 controls). C) CBC analysis of 
leukocyte frequency. D) Frequency of YFP+ leukocytes in peripheral blood. E) Frequency of 
myeloid and lymphoid progeny in peripheral blood. F,G) Hemoglobin and platelet 
abundance in peripheral blood). H) Overall survival.
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Figure 6. Macrophage analysis in CSF1R-MCM+;ROSAYFP;PTPN11E76K animals
Analyses were performed 52-60 weeks after birth following in utero exposure to 4OHT at 
E8.5. A,B) Normalized weights of spleens and livers. C,D) Frequency of B-cells, T-cells, 
and myeloid cells in the bone marrow and spleen of mutants and littermates as measured by 
flow cytometry. E,F) Frequency of YFP+ macrophages (CD45+ CD11b+ F4/80+). G) 7 day 
methylcellulose colony formation from splenic progenitors cultured in in 10ng/ml GM-CSF. 
H) PCR analysis detects recombined LSL-PTPN11E76K locus in genomic DNA from mutant 
brain samples. Image is a concatenation of lanes run on a single gel. I) p-ERK expression in 
microglia following stimulation with 10ng/ml GM-CSF for indicated durations. (N=5 
mutant and 12 controls). J) Representative p-ERK expression in freshly-harvested, 
unstimulated microglia.
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